Company: Abbott Laboratories
Ticker: ABT
Form: 10-K
Filed: 2026-02-20
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Abbott Laboratories's operating cash flow in fiscal year 2025?
Question Type: value_lookup

Concept: NetCashProvidedByUsedInOperatingActivities
Answer (Numeric): 9566.0
Answer (Display): $9,566 million
Unit: USD millions

Evidence:
[{"chunk_id": "116", "equivalent_chunk_ids": ["116"], "section": "Consolidated Statement of Cash Flows", "supports": ["main"], "text": "(in millions)\nYear Ended December 31\nCash Flow From (Used in) Operating Activities:\nNet earnings\n6,524\n13,402\n5,723\nAdjustments to reconcile earnings to net cash from operating activities —\nDepreciation\n1,434\n1,340\n1,277\nAmortization of intangible assets\n1,682\n1,878\n1,966\nShare-based compensation\nInvesting and financing losses, net\nTrade receivables\nInventories\nPrepaid expenses and other assets\n1,295\nTrade accounts payable and other liabilities\nIncome taxes\n8,028\nNet Cash From Operating Activities\n9,566\n8,558\n7,261\nCash Flow From (Used in) Investing Activities:\nAcquisitions of property and equipment\n2,171\n2,207\n2,202\nAcquisitions of businesses and technologies, net of cash acquired\nProceeds from business dispositions\nPurchases of investment securities\nProceeds from sales of investment securities\nOther\nNet Cash From (Used in) Investing Activities\n2,422\n2,338\n3,133\nCash Flow From (Used in) Financing Activities:\nProceeds from issuance of (repayments of) short-term debt, net and other\nProceeds from issuance of long-term debt and debt with maturities over 3 months\nRepayments of long-term debt and debt with maturities over 3 months\n1,504\n2,498\nPurchases of common shares\n1,295\n1,227\nProceeds from stock options exercised\nDividends paid\n4,116\n3,836\n3,556\nOther\nNet Cash From (Used in) Financing Activities\n6,309\n5,404\n7,091\nEffect of exchange rate changes on cash and cash equivalents\nNet Increase (Decrease) in Cash and Cash Equivalents\n2,986\nCash and Cash Equivalents, Beginning of Year\n7,616\n6,896\n9,882\nCash and Cash Equivalents, End of Year\n8,522\n7,616\n6,896\nSupplemental Cash Flow Information:\nIncome taxes paid\n1,933\n1,723\n1,475\nInterest paid\nThe accompanying notes to consolidated financial statements are an integral part of this statement.\nAbbott Laboratories and Subsidiaries"}]

Derivation: